SCHEMBL4376950

SCHEMBL4376950

CCCCc1ccc(S(=O)(=O)N2CCC(=NOCc3cccc(OC(F)(F)F)c3)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 4/20 0.39
MAPT P10636 3/20 0.39
HTT P42858 2/20 0.39
PKM P14618 2/20 0.39
POLB P06746 2/20 0.39
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GAA P10253 1/20 0.37
MMP1 P03956 1/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
MMP13 P45452 1/20 0.37
CD4 P01730 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4393170 0.89 PKM (0.49) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4381771 0.88 LMNA (0.50) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4385481 0.85 LMNA (0.49) LMNASMN1; SMN2ALDH1A1MAPTFAAH
SCHEMBL4393905 0.84 SMN1; SMN2 (0.49) LMNASMN1; SMN2ALDH1A1PKMFAAH
SCHEMBL4383812 0.82 LMNA (0.48) LMNASMN1; SMN2ALDH1A1MAPTFAAH
SCHEMBL4376994 0.82 HSD11B1 (0.42) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4381221 0.82 LMNA (0.43) LMNASMN1; SMN2ALDH1A1MAPTFAAH
SCHEMBL4391160 0.81 KMT2A (0.55) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4380572 0.81 MEN1 (0.43) LMNASMN1; SMN2ALDH1A1PKMMEN1
SCHEMBL4383719 0.80 MEN1 (0.42) LMNASMN1; SMN2ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 LMNA 3822/4885SMN1; SMN2 664/4885ALDH1A1 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.